肿瘤科（内科）

以下为当前的临床试验。

按位置、状态和其他条件筛选该研究列表。

1. Spinal Cord Stimulation To Treat Chemotherapy-Induced Peripheral Neuropathy

   Rochester, Minn.

   The purpose of this study is to understand pain outcomes in patients with cancer who have Chemotherapy-Induced Peripheral Neuropathy (CIPN).

2. A Study To Evaluate If New Tests (“biomarkers”) Of Blood, Stool, Pancreas Cyst Fluid, Or Pancreas Juice Can Be Used To Diagnose Malignant Or Pre-malignant Changes In People With Pancreas Cysts

   Rochester, Minn.

   The goal of this protocol is to collect biospecimens in order to prospectively evaluate diagnostic and prognostic performance of MDMs for detection of advanced neoplasia in pancreatic cysts. 

3. A Study Of Endometrial Cancer Testing With Vaginal And Endometrial Cell Samples

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to collect vaginal and endometrial cell samples to study endometrial cancer.

4. A Study To Identify Biomarkers In The Blood, Saliva Or Tissue For Oropharyngeal Squamous Cell Cancer

   Rochester, Minn.

   The purpose of this study is to identify a biomarker (or biomarkers) that is present when disease is present (i.e., at diagnosis or recurrence) and not present when disease is absent (i.e., after treatment, in HPV negative patients or in normal controls).

5. A Study to Evaluate the Safety and Tolerability of HMPL-306 to Treat Advanced or Metastatic Solid Tumors with IDH Mutations

   Rochester, Minn.

   The purpose of this study is to evaluate the safety, tolerability, and preliminary effectiveness of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.

6. A Study to Evaluate Mutanome-directed Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck

   Jacksonville, Fla.

   The purpose of this study is to evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active immunotherapy (TG4050) in patients with newly-diagnosed, locoregionally advanced, HPV-negative Squamous Cell Carcinoma of the Head and Neck (SCCHN) initiated at completion of primary treatment (Arm A) or at the time of recurrence (Arm B)

7. A Study to Assess Endometrial Cancer Recurrence in Patients After 36 Months

   Rochester, Minn.

   The purpose of this study is to assess the 36-month incidence of pelvic/non-vaginal recurrence among patients with surgical stage I intermediate-risk endometrial cancer.

   Eligible patients presenting with apparent uterine confined grade 1, 2, or 3 endometrioid endometrial cancer will undergo standard-of-care primary surgical treatment with a cervical injection of indocyanine green (ICG) dye for SLN mapping, a total hysterectomy, removal of the adnexae and staging with sentinel node mapping and pelvic washings. 

   The final assessment for inclusion in the follow-up part of the study will be determined from the results of the final hysterectomy and staging pathology report to ensure bilaterally negative pelvic sentinel nodes and a surgical stage I endometrioid endometrial cancer grade 1 or 2 with 50% or more uterine myoinvasion or grade 3 with less than 50% uterine myoinvasion. Women meeting this criteria will comprise the study cohort and be followed for three years.   

    

8. A Study to Evaluate Thymoma Recurrence

   Rochester, Minn.

   The purpose of this study is to evaluate thymoma recurrence rates in patients who underwent thymectomy.

9. Tumor Treating Fields For The Treatment Of Leptomeningeal Metastases Of The Spine In Patients With Breast Or Lung Cancer

   Jacksonville, Fla.

   This clinical trial evaluates the safety and feasibility of tumor treating fields (TTF) in the treatment of spinal leptomeningeal disease in patients with breast or lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Patients wear the portable Novo TTF-200T device that produces electric fields to target areas on the body to stop the growth of tumor cells. The information from this study will help researchers develop a better treatment for leptomeningeal metastases in the future.

10. Actinium Therapy For Late-stage Aggressive Sarcomas

    Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma.
    
    The main questions the study aims to answer in Phase/Part 1 of the trial are:
    
    * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.
    * What is the most tolerable dose of \[Ac225\]RTX-2358
    * Does the treatment show effectiveness on advanced sarcoma
    
    Participants will:
    
    * Take drug \[Ac225\]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months
    * Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.
    * For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests
    * Remain in long term follow-up for a period of four additional years